Akebia Therapeutics, Inc. (AKBA) Form 8-K Material Events
Akebia Therapeutics, Inc. (AKBA) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: AKBA
CIK: 1517022
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Ernst & Young LLP
Auditor SinceSince 12/31/2016 12:00:00 AM
Lead Engagement PartnerJames Belliveau
Audit LocationBoston, Massachusetts, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 8-K | 2026-10-14 | 2026-10-07 | 8-K | 0001517022-26-000071 | View SEC Doc Filr Page |
| 4 | 2026-08-10 | 2026-08-06 | PRIMARY DOCUMENT | 0001591467-26-000004 | View SEC Doc Filr Page |
| S-8 | 2026-08-05 | — | S-8 | 0001193125-26-335375 | View SEC Doc Filr Page |
| 10-Q | 2026-08-05 | 2026-06-30 | 10-Q | 0001517022-26-000051 | View SEC Doc Filr Page |
| 8-K | 2026-08-05 | 2026-08-05 | 8-K | 0001517022-26-000050 | View SEC Doc Filr Page |
| 4 | 2026-07-01 | 2026-06-29 | PRIMARY DOCUMENT | 0001762507-26-000004 | View SEC Doc Filr Page |
| 8-K | 2026-06-30 | 2026-06-30 | 8-K | 0001517022-26-000047 | View SEC Doc Filr Page |
| 144 | 2026-06-29 | — | 144 Filing | 0001517022-26-000044 | View SEC Doc Filr Page |
| 4 | 2026-06-22 | 2026-06-17 | PRIMARY DOCUMENT | 0001808317-26-000001 | View SEC Doc Filr Page |
| 4 | 2026-06-22 | 2026-06-17 | PRIMARY DOCUMENT | 0001609480-26-000003 | View SEC Doc Filr Page |
| 4 | 2026-06-22 | 2026-06-17 | PRIMARY DOCUMENT | 0001244159-26-000001 | View SEC Doc Filr Page |
| 4 | 2026-06-22 | 2026-06-17 | PRIMARY DOCUMENT | 0001890219-26-000001 | View SEC Doc Filr Page |
| 8-K | 2026-06-22 | 2026-06-17 | 8-K | 0001517022-26-000043 | View SEC Doc Filr Page |
| 4 | 2026-06-22 | 2026-06-17 | PRIMARY DOCUMENT | 0001204946-26-000001 | View SEC Doc Filr Page |
| 4 | 2026-06-22 | 2026-06-17 | PRIMARY DOCUMENT | 0001248144-26-000001 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-05-12 | — | SCHEDULE 13G Filing | 0000093751-26-000200 | View SEC Doc Filr Page |
| 10-Q | 2026-05-07 | 2026-03-31 | 10-Q | 0001517022-26-000039 | View SEC Doc Filr Page |
| 8-K | 2026-05-07 | 2026-05-07 | 8-K | 0001517022-26-000038 | View SEC Doc Filr Page |
| ARS | 2026-04-29 | 2025-12-31 | ARS | 0001140361-26-017532 | View SEC Doc Filr Page |
| DEFA14A | 2026-04-28 | — | DEFA14A | 0001517022-26-000035 | View SEC Doc Filr Page |
| DEF 14A | 2026-04-28 | 2026-04-28 | DEF 14A | 0001517022-26-000034 | View SEC Doc Filr Page |
| PRE 14A | 2026-04-15 | 2026-04-15 | DEF 14A | 0001517022-26-000029 | View SEC Doc Filr Page |
| 4 | 2026-04-03 | 2026-04-01 | PRIMARY DOCUMENT | 0001635046-26-000005 | View SEC Doc Filr Page |
| 3 | 2026-04-03 | 2026-04-01 | PRIMARY DOCUMENT | 0001635046-26-000004 | View SEC Doc Filr Page |
| 8-K | 2026-04-01 | 2026-03-27 | 8-K | 0001517022-26-000024 | View SEC Doc Filr Page |